In mid-January the biotech company BioNTech SE based in Mainz announced the acquisition of the US-American T-cell therapy specialist Neon Therapeutics from Cambridge, thereby further expanding its immunotherapy pipeline.
Neon Therapeutics develops neoantigen-targeted T-cell therapy approaches, complemented by platform technologies such as their bioinformatics platform RECON or NEO-STIM, a proprietary method for stimulation, activation and expansion of neoantigen-targeted T-cells ex vivo. Their most advanced program NEO-PTC-01 is based on a neoantigen-targeted T-cell therapy, consisting of multiple T-cell populations and targeting patient-specific neoantigens from the tumor.
https://www.pharmaceutical-technology.com/news/deal-news/biontech-acquires-neon-67m/
